106 related articles for article (PubMed ID: 22563673)
1. Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome.
Chen Q; Lin J; Yao DM; Qian J; Qian W; Yang J; Chai HY; Ma JC; Deng ZQ; Wang CZ; Li Y
Br J Haematol; 2012 Jul; 158(2):293-296. PubMed ID: 22563673
[No Abstract] [Full Text] [Related]
2. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia.
Lin J; Chen Q; Yang J; Qian J; Deng ZQ; Qian W; Chen XX; Ma JC; Xiong DS; Ma YJ; An C; Tang CY
Leuk Res; 2014 May; 38(5):601-7. PubMed ID: 24656837
[TBL] [Abstract][Full Text] [Related]
3. The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia.
Chen Q; Lin J; Qian J; Deng ZQ; Qian W; Yang J; Li Y; Chen XX; Ma YJ; Ma JC; Liu Q
Genet Test Mol Biomarkers; 2013 Jun; 17(6):508-11. PubMed ID: 23495895
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome.
Wu DH; Yao DM; Yang L; Ma JC; Wen XM; Yang J; Guo H; Li XX; Qian W; Lin J; Qian J
Leuk Lymphoma; 2017 Jan; 58(1):96-103. PubMed ID: 27244225
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome.
Qian J; Zhu ZH; Lin J; Ming Yao DM; Li Y; Yang J; Wang CZ
Br J Haematol; 2011 Jul; 154(1):153-5. PubMed ID: 21517806
[No Abstract] [Full Text] [Related]
6. Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia.
Li R; Sobreira N; Witmer PD; Pratz KW; Braunstein EM
Haematologica; 2016 Jun; 101(6):e228-31. PubMed ID: 26944477
[No Abstract] [Full Text] [Related]
7. Aberrant methylation of GTPase regulator associated with the focal adhesion kinase (GRAF) promoter is an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Qian Z; Lin J; Yao DM; Zhu ZH; Chen Q; Xiao GF; Li JY
Eur J Haematol; 2010 Aug; 85(2):174-6. PubMed ID: 20374274
[No Abstract] [Full Text] [Related]
8. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.
Lin J; Wang YL; Qian J; Yao DM; Zhu ZH; Qian Z; Xu WR
Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099
[TBL] [Abstract][Full Text] [Related]
11. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.
Abou Dalle I; Kantarjian H; Bannon SA; Kanagal-Shamanna R; Routbort M; Patel KP; Hu S; Bhalla K; Garcia-Manero G; DiNardo CD
Am J Hematol; 2020 Feb; 95(2):227-229. PubMed ID: 31400013
[No Abstract] [Full Text] [Related]
12. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
Wang H; Fan R; Wang XQ; Wu DP; Lin GW; Xu Y; Li WY
Ann Hematol; 2013 Jan; 92(2):199-209. PubMed ID: 23093371
[TBL] [Abstract][Full Text] [Related]
13. ICSBP promoter methylation in myelodysplastic syndromes and acute myeloid leukaemia.
Otto N; Manukjan G; Göhring G; Hofmann W; Scherer R; Luna JC; Lehmann U; Ganser A; Welte K; Schlegelberger B; Steinemann D
Leukemia; 2011 Jul; 25(7):1202-7. PubMed ID: 21475251
[No Abstract] [Full Text] [Related]
14. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
15. [Methylation status of RIZ1 gene promoter in myelodysplastic syndrome].
Xu RR; Xuan LN; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):774-5. PubMed ID: 23336240
[No Abstract] [Full Text] [Related]
16. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.
Zhao X; Yang F; Li S; Liu M; Ying S; Jia X; Wang X
Br J Haematol; 2014 Jun; 165(5):649-58. PubMed ID: 24601943
[TBL] [Abstract][Full Text] [Related]
17. Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia.
Cardoso SR; Ryan G; Walne AJ; Ellison A; Lowe R; Tummala H; Rio-Machin A; Collopy L; Al Seraihi A; Wallis Y; Page P; Akiki S; Fitzgibbon J; Vulliamy T; Dokal I
Leukemia; 2016 Oct; 30(10):2083-2086. PubMed ID: 27133828
[No Abstract] [Full Text] [Related]
18. Inherited DDX41 mutations: 11 genes and counting.
Tawana K; Fitzgibbon J
Blood; 2016 Feb; 127(8):960-1. PubMed ID: 26917736
[No Abstract] [Full Text] [Related]
19. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Qu S; Li B; Qin T; Xu Z; Pan L; Hu N; Huang G; Peter Gale R; Xiao Z
Br J Haematol; 2021 Mar; 192(6):1006-1010. PubMed ID: 32307695
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.
Kanagal-Shamanna R; Hidalgo Lopez JE; Milton DR; Kim HR; Zhao C; Zuo Z; Janania Martinez M; Stingo F; Lee J; Luthra R; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Am J Hematol; 2017 Aug; 92(8):E168-E171. PubMed ID: 28456995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
